Between cycles
Monitor immune change and strength between visits.
Regular full blood counts track the neutrophil count between visits, supporting earlier action while intervention is safest and least costly.
Learn the technologyONCOLOGY
Designed to support earlier intervention.
and regular monitoring where high-cost events may be reduced.
POTENTIAL FOR
50K - 65K
UK febrile neutropenia patients a year
30 – 40%
Reduction in avoidable admissions (modelled)
£350m – £650m
Estimated annual system saving (projected)
The problem
A signal that arrives too late.
01
Late detection
Around 15 – 20% of chemotherapy patients may develop febrile neutropenia, often identified only after a high-cost emergency admission.
02
Reactive testing
Reactive blood tests miss the window where intervention is cheapest and safest.
03
Treatment gaps
Delayed or skipped cycles compromise efficacy and survival risking treatment continuity.
04
Potential to reduce high-cost events
Avoidable admissions, sepsis and ICU escalations drive cost and most of the harm.
Cycle adherence
Help keep treatment on schedule.
Earlier detection means potential for fewer skipped cycles, potential fewer dose reductions, and potential fewer avoidable admissions — key drivers of survival.
How it works
Closer to patient or at home, every cycle.
A small sample on a cartridge run on the Algocyte Proxima device under healthcare professional supervision returns a full blood count on the spot. Results flow to the clinician's dashboard within minutes not hours or days.
Meet Algocyte® Proxima™How a cycle looks.
01
Test where the patient is located
A single cartridge, about 20 minutes. No phlebotomist required.
02
Build a better baseline
Every test refines the patient's personal reference range.
03
Spot the drift
Spot meaningful deviation in immune and blood markers.
04
Allows to act earlier
Care team can pick up meaningful signals early.
Use Cases.
Bring regular precision and predictive monitoring to users and patients.
See Algocyte in action.